Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update Meeting Abstract
| Authors: | Rea, D.; Mauro, M. J.; Hochhaus, A.; Boquimpani, C.; Lomaia, E.; Voloshin, S.; Turkina, A. G.; Kim, D. W.; Apperley, J.; Cortes, J. E.; Sasaki, K.; Kapoor, S.; Allepuz, A.; Quenet, S.; Bédoucha, V.; Minami, Y. |
| Abstract Title: | Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301905 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.7004 |
| Notes: | Meeting Abstract: 7004 -- Meeting also held virtually -- Source: Wos |
